Actively Recruiting
A Multicenter Real-World Registry of Characteristics, Treatment Strategies, and Clinical Outcomes in Chinese Adults With Chronic Kidney Disease
Led by AstraZeneca · Updated on 2026-05-12
3000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are conducting a prospective, multicenter, observational registry study to better understand treatments, clinical practices, and outcomes related to chronic kidney disease (CKD) in Chinese patients. This study aims to explore cardiorenal risks and differences in treatment approaches across various healthcare settings in China. The study is designed to reflect real-world clinical care and involves multiple hospitals and medical centers across the country. Approximately 3000 participants will be enrolled from about 80 diverse sites including top-tier tertiary hospitals, regional medical centers, and secondary hospitals to represent clinical practice at different care levels. Participants with CKD will be followed for up to 96 weeks. Data will be collected from their medical records and entered into a cloud-based electronic system to ensure quality and accuracy. Investigators will obtain informed consent before enrollment and assign unique identifiers to each participant. Participants will be monitored through medical record reviews up to 96 weeks to assess long-term clinical outcomes, including the presence of comorbidities such as hypertension, heart failure, and hyperkalemia. The study will track medication use, clinical indicators, and health resource utilization. Researchers will analyze these data to understand treatment patterns and outcomes in CKD patients. The study's overall duration and follow-up plan allow for comprehensive observation of disease progression and care strategies.
CONDITIONS
Brief Title
A Prospecitve Multicenter, Observational Registry Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female patients aged 18 years or older
- Willing and able to provide written informed consent to participate
- Confirmed diagnosis of chronic kidney disease defined by either eGFR less than 60 mL/min/1.73 m² for 3 months or more
- Evidence of kidney damage persisting for 3 months or more, such as elevated urine albumin or protein levels, structural abnormalities on imaging, or biopsy findings consistent with chronic kidney injury
You will not qualify if you...
- Life-threatening comorbidity with life expectancy less than 2 years
- Severe cardiac disease including life-threatening arrhythmias or recent major cardiovascular events within the past 3 months
- Pregnant or breastfeeding women
- Currently enrolled in any interventional clinical trial or receiving investigational therapy within 3 months
- Presenting with end-stage renal disease, renal replacement therapy, acute kidney injury, or acute kidney disease as primary condition at enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 96 weeks
Participants who undergo routine care are observed, and clinical data are collected from medical records to assess long-term outcomes.
Follow-up visits according to routine healthcare visits up to 96 weeks
Trial Site Locations
Total: 1 location
1
Zhongshan Hospital Affilicated with Fudan University
Shanghai, China
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here